• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    M

    Mount Sinai Hospital (Manhattan)

    4,822论文总数
    16.6万引用总数

    Mount Sinai Hospital, founded in 1852, is one of the oldest and largest teaching hospitals in the United States. It is located in East Harlem in the New York City borough of Manhattan, on the eastern border of Central Park stretching along Madison and Fifth Avenues, between East 98th Street and East 103rd Street. The entire Mount Sinai health system has over 7,400 physicians, as well as 3,815 beds, and delivers over 16,000 babies a year. In 2019–20, the hospital was ranked 14th among the nearly 5,000 hospitals in the US by the U.S. News & World Report.

    论文量&引用量时间轴

    机构学者

    论文(4822)

    年份
    起
    –
    止
    排序
    1[Recommendations for the Diagnosis and Treatment of Optic Neuromyelitis in Children and Adolescents].
    Bolívar Quito-Betancourt, Juan Contreras, Francisco Espinel, María Teresa Acosta

    Neuromyelitis Optica spectrum disorder (NMOSD) is a severe autoimmune disease of the central nervous system characterized primarily by inflammation of the optic nerve, spinal cord, and brainstem. The identification of IgG antibodies against aquaporin-4 (AQP4-IgG) has transformed the understanding and classification of the disease, distinguishing it from other inflammatory CNS disorders. However, some seronegative patients remain a subject of debate.

    2026Medicina(2026)
    引用
    AI阅读
    加入学术空间
    2[Guide to Approaching the First Demyelinating Event in Pediatrics].
    Andrea Savransky, Andrea Del Rocío Quiroz Saavedra, Bolivar Quito-Betancourt, Ruth Elizabeth Chávez, Luz Monti, Maria Celeste Buompadre

    Isolated demyelinating syndrome (IDS), or first demyelinating event, is defined as an acute neurological presentation associated with central nervous system (CNS) demyelination. It may occur as a monophasic episode or represent the initial manifestation of a recurrent demyelinating disorder. IDS is classified as either monofocal -affecting the brain, brainstem, cerebellum, optic nerve, or spinal cord-or multifocal, when a combination of these regions is involved. Management is primarily directed toward optimizing functional recovery. Additionally, in patients who fulfill diagnostic criteria for an underlying demyelinating disease, the initiation of immunosuppressive therapy should be considered.

    2026Medicina(2026)
    引用
    AI阅读
    加入学术空间
    3LONG-TERM OUTCOMES OF POSTNATAL IMMUNOSUPPRESSIVE THERAPY IN CHILDREN WITH CARDIAC NEONATAL LUPUS ERYTHEMATOSUS
    Chinmayi Yathiraju, Kendal Thompson,Talia Diaz,Daniela Dominguez,Lindsay Freud,Robert Hamilton,Carl Laskin,Earl Silverman,Linda Hiraki

    Objectives Neonatal lupus erythematosus (NLE) is a passively acquired autoimmune condition. The antibody-mediated neonatal heart disease of NLE is associated with a high risk of mortality and adverse health outcomes. Prenatal treatment can slow progression to complete heart block and improve neonatal survival, but the impacts of postnatal immunosuppressant treatment have not been described. This study describes the outcomes of children with antibody-mediated cardiac NLE treated with postnatal therapy. Methods We reviewed patients consented from the LE clinic in a tertiary pediatric center born between January 1, 1997 - June 10, 2024. We identified patients with cardiac manifestations who received postnatal immunosuppressants. The protocol typically included 1 dose of intravenous immunoglobulin (IVIG) 2g/kg, pulse corticosteroid of 30 mg/kg/day for 3 days, followed by 2 mg/kg/day for 4 weeks with tapering guided by troponin levels. We reviewed medical records with long-term outcomes supplemented by patient/parent questionnaires. We report the prevalence of features and outcomes using summary statistics. Results We reviewed 33 patients with cardiac manifestations of NLE and postnatal therapy. Of the total cohort, 28 (85%) mothers received prenatal immunosuppressive therapy with dexamethasone, IVIG and/or a beta agonist. The median duration of follow-up was 6.04 years (IQR: 2.47 - 11.36 years). The majority (70%) of patients presented with heart block at birth (first-degree/second-degree atrioventricular block [n=7], complete heart block [n=16]). The remaining 10 patients had extranodal manifestations of cardiac inflammation, including echogenic endocardium and valvular regurgitation. Of the 7 patients with first or second-degree block at birth, 4 progressed to complete heart block within an average of 11 months. One patient with first-degree block had complete reversal to normal sinus rhythm. Of the 18 (70%) patients that required a permanent pacemaker, 83% were paced within the first year of life. Of all patients that developed complete heart block in their lifetime, 2 never required pacing (age at last follow-up 17.38 and 19.25 years). No patients required a heart transplant. Three patients developed device-associated or sternal wound infections an average of 1.1 months after birth. Mortality in the cohort was 9% with cause of death attributed to circulatory shock due to sepsis and an unrelated genetic syndrome. Conclusion We report on the outcomes of a large series of children with cardiac NLE who received postnatal immunosuppressive therapy. The vast majority of patients had good outcomes. Postnatal immunosuppressive therapy may be responsible for improved cardiovascular outcomes in children with antibody-mediated neonatal heart disease.

    2026JOURNAL OF RHEUMATOLOGY(2026)
    引用
    AI阅读
    加入学术空间
    4Age-related Changes in Body Composition: a Cross-Sectional Study from a Single Center in Buenos Aires, Argentina.
    Rubén Abdala,Lorena Conejos, Diana G Garate Correa,Giselle Mumbach,Mailen Gonzalez,Mariela Sesta,Fernando Jerkovich,María B Zanchetta

    INTRODUCTION:Several physiological changes occur during the aging process, with perhaps the most apparent being modifications in body composition. The objective was to evaluate ongoing changes in body composition, throughout the aging process. MATERIALS AND METHODS:A cross-sectional study was conducted in 975 participants (612 women, 363 men) aged 18-89 years, whose body composition was assessed using dual-energy X-ray absorptiometry (DXA). RESULTS:The mean age was 48 ± 17 years for women and 43 ±15 years for men (p < 0.01). Men exhibited a greater amount of lean mass compared to women (54.5 ± 9.4 vs. 37.7 ± 5.5 kg; p<0.0001). Women showed a higher percentage of lower limb lean mass than men (78 vs. 74%; p < 0.05). Age was independently associated with decreased appendicular muscle mass, with a reduction of 0.38 kg per decade. On the other hand, women exhibited higher relative fat mass and a greater proportion of lean tissue in the lower limbs. Fat tissue increased with age in both sexes, remaining consistently higher in women. Lean mass and bone mineral content peaked in the second and third decades of life and declined thereafter. CONCLUSION:This study highlights the changes in body composition at various life stages, revealing a peak gain of lean tissue between the second and third decades, followed by a decline in subsequent years. To our knowledge, this is the first study that evaluates the changes in body composition in our country.

    2026Medicina(2026)
    引用
    AI阅读
    加入学术空间
    5Epigenetic Profiling of Human Insulinomas Reveals AP-1 Family As Critical Regulators of Beta Cell Maturation
    Xuedi Wang, Saul Carcamo,Luca Lambertini,Peng Wang,Hongtao Liu, John D. Paulsen,Rachel Brody, Gustavo Fernandez-Ranvier, Dan Hasson, Andrew F. Stewart,Esra Karakose

    Summary Insulinomas are rare and benign human pancreatic adenomas that overproduce insulin and display increased beta cell mass. We and others have shown that transcriptomic and genomic profiling on insulinomas provides a data mine for identifying targets that can be manipulated to induce human beta cell regeneration. Majority of causative genetic variants in insulinomas involve epigenetic regulatory genes. Yet, specifically how these variants lead to human beta cell expansion and increased function is largely unknown. Here, we performed bulk and single-nucleus epigenomic and transcriptomic profiling to define regulatory alterations in human insulinomas. Bulk ATAC-seq and H3K27Ac ChIP-seq revealed significant enrichment of AP-1 transcription factor binding motifs within beta cell-associated open chromatin/enhancer regions in normal islets, accompanied by robust expression of AP-1 family members; in contrast, insulinomas exhibited marked reductions in both AP-1 motif enrichment and AP-1 expression. Our snRNA-seq and snATAC-seq profiling across four independent insulinomas identified a consistent and previously unrecognized signature defined by suppression of AP-1 transcription factors and widespread loss of chromatin accessibility at AP-1 binding sites, particularly at enhancers governing beta cell identity. Collectively, these results establish AP-1-mediated regulatory programs as critical determinants of beta cell maturation and define their disruption as a signature among human insulinomas.

    2026
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 4822 篇论文

    合作机构(100)

    多伦多大学合作论文 776
    多伦多大学健康网络合作论文 237
    麦克马斯特大学合作论文 159
    McGill University合作论文 152
    哥伦比亚大学合作论文 143
    Mount Sinai Hospital,Sinai Health System合作论文 136
    桑尼布洛克健康科学中心合作论文 119
    伦敦安大略西部大学合作论文 117
    约翰斯·霍普金斯大学合作论文 106
    曼尼托巴大学合作论文 104

    机构统计